X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (381) 381
humans (299) 299
endocrinology & metabolism (284) 284
type 2 diabetes (251) 251
glp-1 (249) 249
glp‐1 (247) 247
male (223) 223
diabetes (222) 222
diabetes mellitus, type 2 - drug therapy (217) 217
glucagon (197) 197
female (177) 177
insulin (158) 158
glucagon-like peptide-1 (155) 155
glucose (153) 153
diabetes mellitus (143) 143
middle aged (136) 136
liraglutide (131) 131
hypoglycemic agents - therapeutic use (127) 127
animals (118) 118
diabetes mellitus, type 2 - blood (106) 106
exenatide (99) 99
glp‐1 analogue (94) 94
glp-1 analogue (93) 93
diabetes therapy (91) 91
glycosylated hemoglobin (91) 91
adult (90) 90
glycemic control (90) 90
hypoglycemic agents - administration & dosage (90) 90
peptides (90) 90
analysis (87) 87
metformin (87) 87
clinical trials (86) 86
dextrose (86) 86
hypoglycemic agents (85) 85
aged (84) 84
blood glucose - metabolism (84) 84
blood glucose - drug effects (77) 77
safety (77) 77
diabetes mellitus, type 2 - metabolism (73) 73
obesity (73) 73
open-label (72) 72
body weight (71) 71
hypoglycemic agents - adverse effects (71) 71
double-blind (69) 69
treatment outcome (69) 69
original (68) 68
glucagon-like peptide 1 - analogs & derivatives (65) 65
glucagon-like peptide-1 receptor - agonists (64) 64
glycated hemoglobin a - metabolism (60) 60
double-blind method (59) 59
original articles (59) 59
glucagon-like peptide-1 receptor (58) 58
efficacy (55) 55
hypoglycemia (55) 55
care and treatment (54) 54
hemoglobin (54) 54
hypoglycemic agents - pharmacology (54) 54
original article (54) 54
drug administration schedule (52) 52
rats (49) 49
glucagon-like peptide 1 (48) 48
pharmacology & pharmacy (48) 48
mice (47) 47
secretion (46) 46
body mass index (43) 43
dose-response relationship, drug (43) 43
glp-1 receptor agonist (43) 43
glucose metabolism (43) 43
glycated hemoglobin a - drug effects (43) 43
beta-cell function (42) 42
peptides - therapeutic use (42) 42
diabetes mellitus, type 2 - complications (41) 41
drug therapy, combination (41) 41
glp-1 receptor agonists (41) 41
glucagon-like peptide 1 - therapeutic use (41) 41
insulin - metabolism (41) 41
evidence-based medicine (40) 40
glp‐1 receptor agonist (40) 40
hypoglycemia - chemically induced (40) 40
patients (40) 40
type-2 diabetes-mellitus (40) 40
antidiabetic drug (39) 39
blood sugar (39) 39
exendin-4 (39) 39
glycaemic control (39) 39
insulin secretion (38) 38
rodents (38) 38
glucagon-like peptide-1 receptor - metabolism (37) 37
body weight - drug effects (36) 36
peptides - administration & dosage (36) 36
receptors, glucagon - agonists (36) 36
weight loss - drug effects (36) 36
hyperglycemia (35) 35
randomized controlled trials as topic (35) 35
peptides - pharmacology (34) 34
risk factors (34) 34
glucagon-like peptide 1 - metabolism (33) 33
incretin therapy (33) 33
sitagliptin (33) 33
glp‐1 receptor agonists (32) 32
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 10/2012, Volume 14, Issue 10, pp. 910 - 917
Aims To assess the efficacy and safety of once‐daily lixisenatide versus placebo in Asian patients with type 2 diabetes insufficiently controlled on basal... 
basal insulin | type 2 diabetes | Asian patients | GLP‐1 | lixisenatide | Type 2 diabetes | Basal insulin | GLP-1 | Lixisenatide | METFORMIN | GLYCEMIC CONTROL | EFFICACY | SAFETY | EXENATIDE | PEPTIDE-1 ANALOG LIRAGLUTIDE | HYPERGLYCEMIA | ENDOCRINOLOGY & METABOLISM | JAPANESE PATIENTS | WEIGHT | GLIBENCLAMIDE | Japan - epidemiology | Hypoglycemia - epidemiology | Receptors, Glucagon - antagonists & inhibitors | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Peptides - administration & dosage | Diabetes Mellitus, Type 2 - epidemiology | Dose-Response Relationship, Drug | Hypoglycemic Agents - administration & dosage | Sulfonylurea Compounds - pharmacology | Philippines - epidemiology | Postprandial Period | Aged, 80 and over | Adult | Female | Hypoglycemia - blood | Sulfonylurea Compounds - administration & dosage | Drug Therapy, Combination | Republic of Korea - epidemiology | Body Mass Index | Insulin - pharmacology | Double-Blind Method | Drug Administration Schedule | Blood Glucose | Insulin - administration & dosage | Treatment Outcome | Hypoglycemia - drug therapy | Hypoglycemic Agents - pharmacology | Peptides - pharmacology | Asian Continental Ancestry Group | Diabetes Mellitus, Type 2 - blood | Glucagon-Like Peptide-1 Receptor | Taiwan - epidemiology | Adolescent | Aged | Diabetes Mellitus, Type 2 - drug therapy | Clinical trials | Blood sugar | Insulin | Diabetes therapy | Original
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 04/2016, Volume 18, Issue 4, pp. 317 - 332
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 12/2016, Volume 18, Issue 12, pp. 1176 - 1190
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 09/2017, Volume 19, Issue 9, pp. 1233 - 1241
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 05/2011, Volume 13, Issue 5, pp. 394 - 407
Incretin‐based therapies, such as the injectable glucagon‐like peptide‐1 (GLP‐1) receptor agonists and orally administered dipeptidyl peptidase‐4 (DPP‐4)... 
albiglutide | GLP‐1 analogue | CJC‐1134‐PC | GLP‐1 receptor agonists | antidiabetic drug | type 2 diabetes mellitus | LY2189265 | taspoglutide | exenatide once weekly | incretin therapy | Incretin therapy | Exenatide once weekly | Antidiabetic drug | GLP-1 receptor agonists | GLP-1 analogue | Taspoglutide | CJC-1134-PC | Albiglutide | Type 2 diabetes mellitus | HUMAN GLP-1 ANALOG | INSULIN-SECRETION | OPEN-LABEL | INADEQUATE GLYCEMIC CONTROL | TWICE-DAILY EXENATIDE | BODY-WEIGHT | BETA-CELL-FUNCTION | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | ACUTE-PANCREATITIS | TYPE-2 DIABETES-MELLITUS | Glucagon-Like Peptide 1 - administration & dosage | Recombinant Fusion Proteins - pharmacology | Glycated Hemoglobin A - metabolism | Humans | Glycated Hemoglobin A - drug effects | Male | Immunoglobulin Fc Fragments - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Hyperglycemia - drug therapy | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Glucagon-Like Peptides - analogs & derivatives | Recombinant Fusion Proteins - administration & dosage | Receptors, Glucagon - agonists | Glucagon-Like Peptide 1 - analogs & derivatives | Glucagon-Like Peptide 1 - pharmacology | Biomarkers - blood | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Hypoglycemic Agents - pharmacology | Peptides - pharmacology | Glucagon-Like Peptide-1 Receptor | Immunoglobulin Fc Fragments - pharmacology | Venoms - pharmacology | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Liraglutide | Type 2 diabetes | Antigen-antibody reactions | Hyperglycemia | Peptides | Heterocyclic compounds | Glycosylated hemoglobin | Hypoglycemic agents | Glucose | Dextrose
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 07/2017, Volume 19, Issue 7, pp. 1024 - 1031
Aim To compare the addition of weekly dulaglutide vs the addition of placebo to titrated glargine in patients with type 2 diabetes (T2D) with sub‐optimum... 
type 2 diabetes | dulaglutide | GLP‐1 receptor agonists | insulin glargine | AWARD‐9 | GLP-1 receptor agonists | AWARD-9 | METFORMIN | FIXED-RATIO COMBINATION | DAILY LIXISENATIDE | EXENATIDE | MELLITUS | ORAL-AGENTS | LIRAGLUTIDE | BASAL INSULIN | ENDOCRINOLOGY & METABOLISM | HUMAN NPH INSULIN | HYPOGLYCEMIA | Glucagon-Like Peptide-1 Receptor - antagonists & inhibitors | Glycated Hemoglobin A - analysis | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Patient Dropouts | Immunoglobulin Fc Fragments - administration & dosage | Hypoglycemia - prevention & control | Insulin Glargine - administration & dosage | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Female | Immunoglobulin Fc Fragments - therapeutic use | Drug Therapy, Combination | Hypoglycemia - chemically induced | Glucagon-Like Peptides - analogs & derivatives | Drug Resistance | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Insulin Glargine - adverse effects | Double-Blind Method | Drug Administration Schedule | Insulin Glargine - therapeutic use | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Incretins - adverse effects | Intention to Treat Analysis | Aged | Glucagon-Like Peptides - therapeutic use | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Monitoring | Hypoglycemic Agents - adverse effects | Incretins - administration & dosage | Type 2 diabetes | Clinical trials | Glycosylated hemoglobin | Glucagon | Insulin | Analysis | Hypoglycemia | Evidence-based medicine | Diabetes
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2017, Volume 19, Issue 2, pp. 162 - 171
Journal Article
Journal Article